New Zealand markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
13.07-0.16 (-1.21%)
At close: 04:00PM EDT
13.05 -0.02 (-0.15%)
After hours: 06:07PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

Currency in JPY. All numbers in thousands
Breakdown
ttm
31/03/2023
31/03/2022
31/03/2021
Cash flows from operating activities
Net income
178,219,000
317,017,000
230,059,000
376,005,000
Depreciation & amortisation
702,668,000
664,400,000
583,151,000
559,671,000
Deferred income taxes
-30,099,000
58,052,000
72,405,000
-9,936,000
Stock-based compensation
67,532,000
60,672,000
43,374,000
37,663,000
Change in working capital
-171,987,000
-25,264,000
98,605,000
275,781,000
Inventory
-173,405,000
-79,155,000
-46,148,000
25,978,000
Other working capital
-129,035,000
343,467,000
937,068,000
774,463,000
Other non-cash items
4,434,000
18,006,000
184,314,000
120,717,000
Net cash provided by operating activities
731,449,000
977,156,000
1,123,105,000
1,010,931,000
Cash flows from investing activities
Investments in property, plant and equipment
-860,484,000
-633,689,000
-186,037,000
-236,468,000
Acquisitions, net
-
0
-49,672,000
0
Purchases of investments
-9,434,000
-10,151,000
-8,341,000
-12,596,000
Sales/maturities of investments
2,790,000
22,254,000
16,921,000
74,604,000
Other investing activities
-2,917,000
-3,052,000
-7,327,000
-10,343,000
Net cash used for investing activities
-840,870,000
-607,102,000
-198,125,000
393,530,000
Cash flows from financing activities
Debt repayment
-450,187,000
-400,071,000
-849,809,000
-1,690,976,000
Common stock repurchased
-2,326,000
-26,929,000
-77,531,000
-2,141,000
Dividends paid
-288,481,000
-279,416,000
-283,665,000
-283,357,000
Other financing activities
43,878,000
-9,177,000
-385,000
-35,002,000
Net cash used provided by (used for) financing activities
-302,793,000
-709,149,000
-1,070,265,000
-1,088,354,000
Net change in cash
-412,213,000
-339,094,000
-145,285,000
316,107,000
Cash at beginning of period
685,141,000
849,695,000
966,222,000
637,614,000
Cash at end of period
272,927,000
533,530,000
849,695,000
966,222,000
Free cash flow
Operating cash flow
731,449,000
977,156,000
1,123,105,000
1,010,931,000
Capital expenditure
-860,484,000
-633,689,000
-186,037,000
-236,468,000
Free cash flow
-129,035,000
343,467,000
937,068,000
774,463,000